Young researchers working in Europe are invited to apply for the Eppendorf Award for Young European Investigators.
Researchers who are less than 35 have until 15 January 2012 to apply.
The award, inaugurated in 1995, acknowledges outstanding contributions to biomedical research in Europe based on methods of molecular biology, including novel analytical concepts.
An independent expert committee chaired by Kai Simons of the Max Planck Institute for Molecular Cell Biology and Genetics, in Dresden, Germany, will choose the winner.
The successful entrant will receive €15,000 in prize money and an invitation to the prize-giving ceremony at the EMBL Advanced Training Centre in Heidelberg, Germany on 9 May 2012.
In addition, he/she will be invited to Eppendorf in Hamburg and coverage of his/her work will be published in Nature magazine and in a podcast.
The official registration portal is at www.eppendorf.com/award/application. Only online registrations will be accepted.
Full details on the Eppendorf Award, the selection criteria and past award winners, are available at www.eppendorf.com/award.
Eppendorf Award for Young European Investigators opens for entry
Deadline is 15 January 2012
You may also like
Regulatory
![Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS]()
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS
The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Research & Development
![Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker]()
Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker
New homogeneous, plate-based assay enables researchers to track hKi-67 in a simple add-and-read format, delivering robust and reproducible results in less time
Research & Development
![BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset]()
BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset
The deal, worth up to $800m including milestones, marks BioArctic's fourth BrainTransporter partnership — joining existing collaborations with Eisai, Bristol Myers Squibb and Novartis to advance brain-targeted biologics delivery
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
![Mabion and Oddifact to explore orphan drug potential of MabionCD20 through new collaboration]()
Mabion and Oddifact to explore orphan drug potential of MabionCD20 through new collaboration
Mabion has signed a letter of intent with Oddifact to reposition its Phase III-stage CD20 monoclonal antibody candidate for rare disease indications, leveraging AI-driven orphan drug identification and existing manufacturing expertise
